Overview
Bodyport helps people with chronic heart conditions by combining at-home devices with a biomarker platform that noninvasively measures hemodynamic biomarkers. At-home devices collect measurements that the platform turns into actionable health insights and alerts for patients and care teams. It differentiates itself by offering noninvasive, at-home monitoring together with an integrated digital platform for ongoing, data-driven heart-health management outside clinics. Its goal is to reduce hospital visits and improve outcomes through easy-to-use monitoring and timely insights.
Work here?Claim your company
Simplify's take
What believers are saying
- Sutter Health launched heart-failure monitoring with Bodyport on October 21, 2026.
- Bodyport reported Congestion Index alerts identified 70% of heart-failure events in SCALE-HF 1.
- The company's October 2026 clinical push positions it for broader health-system expansion in 2027.
What critics are saying
- Bodyport depends on Sutter Sync adoption and one flagship workflow for revenue concentration.
- Competitors like Boehringer-Yale digital-care programs will pressure evidence, pricing, and distribution.
- If reimbursement stalls, hospital procurement freezes and Bodyport becomes a research vendor, not a platform.
What makes Bodyport unique
- FDA-cleared Bodyport Cardiac Scale feeds Epic-integrated heart-failure monitoring at home.
- SCALE-HF 1 tracked 329 patients across eight sites with biomarker alerts.
- Boehringer Ingelheim funded Bodyport and backs the smart-scale category.
Help us improve and share your feedback! Did you find this helpful?
Funding
Notable Investors:
Series A funding typically happens when a startup has a product and some customers, and now needs funding to scale. This money is usually used to grow the team, expand marketing, and improve the product. Venture capital firms are frequently the main investors here.
Series A Funding Comparison
Industry standards
Ind Avg. $15M
$3.7M
$5M
$8.2M
$11.2M
$15M
$30M